Grant: Project Grant
McGill University
$688,500.00
Identify and develop small-molecular-weight compounds for the treatment of ubiquinone deficiency and mitochondrial dysfunction.
EF 2017-18
Résumé
Ubiquinone, also known as Co-enzyme Q10 (CoQ10) is a natural compound found in almost all cells of all organisms, including people. It is absolutely needed for cells to function normally, in particular to be able to produce energy and to fight oxidative stress from free radicals. Patients with an inborn inability to make sufficient amounts of CoQ10 become extremely sick. Furthermore, other types of diseases, for example Parkinson's disease, as well as aging itself, lead to loss of the normal amount of CoQ10. For all these reasons
CoQ10 is provided as a treatment in these disease situations. In addition, it is used by many as an anti-aging nutritional supplement. Unfortunately, the chemical properties of CoQ10 are such that it is very difficult for the body and the cells of the body to absorb it when it is provided in the diet. This is why the positive effects of CoQ10 treatment are often very small or absent, despite the fact that they could in principle be very beneficial. We have been able to develop methods to find new chemical compounds that could allow for an increase in the content of CoQ10 in the body and the cells of patients who could benefit from it. We expect to find two types of chemical compounds that could be used as drugs: 1) Compounds that allow for much better absorption of CoQ10 when it is provided as a supplement, and 2) compounds that boost the natural production of CoQ10 in cells. We will test our compounds in a special type of mice that are engineered to have low CoQ10 levels, which makes them very sick, as well as in mutant mice that are sick because of problems with energy production and difficulties with handling (detoxifying) free radicals.
Programme
Project Grant
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
379736
Name
Hekimi Siegfried
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Aging
Theme2
Biomedical
Prcname2
Cell Biology & Mechanisms of Disease 2
Projecttitle
Identify and develop small-molecular-weight compounds for the treatment of ubiquinone deficiency and mitochondrial dysfunction.
Programtype2
Operating Grants
Orgnameinp2
McGill University
Cihramount2
$688,500
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Aging; In Vivo Modes Of Delivery Of Pharmacological Compounds; Micelles; Mitochondrial Disease Syndrome; Mode Of Action Studies; Mouse Models Of Mitochondrial Dysfunction; Oxidative Stress; Primary And Secondary Ubiquinone Deficiency; Small Molecular Weight Compound Screens; Ubiquinone/Coenzyme Q
Abstract
Ubiquinone, also known as Co-enzyme Q10 (CoQ10) is a natural compound found in almost all cells of all organisms, including people. It is absolutely needed for cells to function normally, in particular to be able to produce energy and to fight oxidative stress from free radicals. Patients with an inborn inability to make sufficient amounts of CoQ10 become extremely sick. Furthermore, other types of diseases, for example Parkinson's disease, as well as aging itself, lead to loss of the normal amount of CoQ10. For all these reasons
CoQ10 is provided as a treatment in these disease situations. In addition, it is used by many as an anti-aging nutritional supplement. Unfortunately, the chemical properties of CoQ10 are such that it is very difficult for the body and the cells of the body to absorb it when it is provided in the diet. This is why the positive effects of CoQ10 treatment are often very small or absent, despite the fact that they could in principle be very beneficial. We have been able to develop methods to find new chemical compounds that could allow for an increase in the content of CoQ10 in the body and the cells of patients who could benefit from it. We expect to find two types of chemical compounds that could be used as drugs: 1) Compounds that allow for much better absorption of CoQ10 when it is provided as a supplement, and 2) compounds that boost the natural production of CoQ10 in cells. We will test our compounds in a special type of mice that are engineered to have low CoQ10 levels, which makes them very sick, as well as in mutant mice that are sick because of problems with energy production and difficulties with handling (detoxifying) free radicals.
Competitiondate
201803
Approvedterm2
5 yrs 0 mth
Pinamesdelim
Hekimi, Siegfried
Approvedterm
5 ans 0 mois
Cihrcontribution2
~ $688,500~ $0~